Evidence map›Paper›PMID 25602801›Full record

ArticleThe American journal of surgical pathology2015

Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions.

Iwei Yeh, Arnaud de la Fouchardiere, Daniel Pissaloux, Thaddeus W Mully, Maria C Garrido, Swapna S Vemula, Klaus J Busam, Philip E LeBoit, Timothy H McCalmont, Boris C Bastian

Abstract read
In one paragraph

Article in The American journal of surgical pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
20.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it, 148 citations in OpenAlex.

  1. Pooled it
  2. [Spitz tumors].Pathologie (Heidelberg, Germany) · 2026
    Review
  3. Article
  4. Gene fusions in melanocytic lesions: an updated comprehensive review.Journal of pathology and translational medicine · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Spitz tumours and mimickers.Virchows Archiv : an international journal of pathology · 2025
    Review
  11. Novel gene fusion discovery in Spitz tumours and its relevance in diagnostics.Virchows Archiv : an international journal of pathology · 2024
    Article
  12. Amplification of Mutant NRAS in Melanocytic Tumors With Features of Spitz Tumors.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2024
    Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Next-generation sequencing in dermatology.Frontiers in medicine · 2023
    Review
  19. [A Case of Advanced Lung Squamous Cell Carcinoma with CLIP1-ALK Fusion Gene].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Iwei Yeh*Departments of Dermatology and Pathology, University of California, San Francisco, CA ‡Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY †Department of Biopathologie, Centre Leon Berard, Leon, France.
Arnaud de la Fouchardiere
Daniel Pissaloux
Thaddeus W Mully
Maria C Garrido
Swapna S Vemula
Klaus J Busam
Philip E LeBoit
Timothy H McCalmont
Boris C Bastian
University of California, San Francisco · USCentre Léon Bérard · FRMemorial Sloan Kettering Cancer Center · US

Funding

TUMOR DEVELOPMENT AND PROGRESSION IN HUMAN MELANOCYTESP01CA025874 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 1985 to 2015
$19.0M
NCI NIH HHS (P01 CA025874NCI NIH HHS P01 CA025874
6 · The paper itself

Abstract

Activating kinase fusions have recently been described as early oncogenic events that are mutually exclusive with HRAS and BRAF mutations in Spitz tumors. Here, we report a series of 32 Spitz tumors with ALK fusions (6 Spitz nevi, 22 atypical Spitz tumors, and 4 spitzoid melanomas) in patients ranging from 5 months to 64 years (median=12 y) of age. The tumors typically presented as exophytic papules on the extremities and were occasionally darkly pigmented. In addition to ALK fusions previously described in other tumor types (NPM1-ALK, TPR-ALK), we identified 2 novel ALK fusions (CLIP1-ALK and GTF3C2-ALK) in our cohort of Spitz tumors. Array comparative genomic hybridization of 19 of these tumors demonstrated a high frequency of chromosome 2 aberrations (where ALK resides, 63%) and chromosome 1p loss in 37% of the cases. Spitz tumors with ALK fusions demonstrated unique histopathologic features. Clefts and small vesicle-like spaces were arrayed between plump spindled melanocytes with fibrillar cytoplasm and enlarged nuclei. These melanocytes were typically arrayed in elongated and fusiform nests with radial orientation. The tumors often had extension into the dermis or subcutis with a wedge-shaped or bulbous lower border (45% and 17%, respectively). An infiltrative growth pattern was often present at the periphery of the tumor and was highlighted by ALK immunohistochemistry. In conclusion, Spitz tumors with ALK rearrangement show distinct histopathologic features that should aid in improving classification of these diagnostically challenging tumors.

Indexed as

AdolescentAnaplastic Lymphoma KinaseChildChild, PreschoolComparative Genomic HybridizationFemaleGenomicsHumansInfantIn Situ Hybridization, FluorescenceMaleMiddle AgedNevus, Epithelioid and Spindle CellNucleophosminOncogene Proteins, FusionReceptor Protein-Tyrosine KinasesALK protein, humanAnaplastic Lymphoma KinaseNPM1 protein, humanNucleophosminOncogene Proteins, FusionReceptor Protein-Tyrosine Kinases

Identifiers

PMID25602801
PMCPMC4398593
OpenAlexW2325333765

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.